Treatment of HASMCs with RUNX1 siRNA resulted in a significant decrease in SLC44A2 levels (Figure 7B), Notably, the RUNX1 level was elevated in aortic samples from patients with AAA (Figure 7, C and D). The gene discussed is SLC44A2; the disease is triple-A syndrome.